Perianal Fistula
1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Arctic TherapeuticsIceland - Reykjavik
1 programInjection of autologous adipose tissue in anal fistulaN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Direct BiologicsExoFlo
Arctic TherapeuticsInjection of autologous adipose tissue in anal fistula
Clinical Trials (2)
Total enrollment: 32 patients across 2 trials
Study of ExoFlo for the Treatment of Perianal Fistulas
Start: Aug 2023Est. completion: Dec 20245 patients
Phase 1/2Terminated
Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas
Start: Jan 2015Est. completion: Feb 202127 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.